beclometasone dipropionate Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
prednisone and prednisolone derivatives	294	5534-09-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: rhinocort beclometasone dipropionate beclomethasone dipropionate beclomethasone dipropionate monohydrate	An anti-inflammatory, synthetic glucocorticoid. It is used topically as an anti-inflammatory agent and in aerosol form for the treatment of ASTHMA. Molecular weight: 521.05 Formula: C28H37ClO7 CLOGP: 4.26 LIPINSKI: 1 HAC: 7 HDO: 1 TPSA: 106.97 ALOGS: -5.40 ROTB: 8 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

rhinocort
beclometasone dipropionate
beclomethasone dipropionate
beclomethasone dipropionate monohydrate

An anti-inflammatory, synthetic glucocorticoid. It is used topically as an anti-inflammatory agent and in aerosol form for the treatment of ASTHMA.

Molecular weight: 521.05
Formula: C28H37ClO7
CLOGP: 4.26
LIPINSKI: 1
HAC: 7
HDO: 1
TPSA: 106.97
ALOGS: -5.40
ROTB: 8

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.40	mg	N
0.80	mg	Inhal.aerosol
0.80	mg	Inhal.powder
1.50	mg	Inhal.solution

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.05 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	0.29 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	36 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.13 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	0.50 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
May 12, 1976	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Asthma	503.25	11.33	402	24056	91140	46570464
Wheezing	185.45	11.33	181	24277	53205	46608399
Dyspnoea	87.42	11.33	513	23945	515035	46146569
Rheumatoid arthritis	75.06	11.33	17	24441	240198	46421406
Death	64.52	11.33	49	24409	335499	46326105
Lip swelling	59.60	11.33	70	24388	25325	46636279
Cough	59.17	11.33	258	24200	229991	46431613
Toxicity to various agents	56.85	11.33	20	24438	211746	46449858
Swelling face	54.65	11.33	99	24359	52960	46608644
Asthmatic crisis	52.41	11.33	22	24436	1456	46660148
Swollen tongue	51.76	11.33	70	24388	29162	46632442
Chest discomfort	49.91	11.33	131	24327	90138	46571466
Drug ineffective	48.77	11.33	187	24271	677651	45983953
Depressed mood	44.73	11.33	70	24388	33249	46628355
Periorbital swelling	41.66	11.33	18	24440	1280	46660324
Bronchospasm	41.43	11.33	46	24412	15661	46645943
Anaphylactic reaction	40.08	11.33	87	24371	53025	46608579
Flashback	39.74	11.33	10	24448	123	46661481
Blood electrolytes abnormal	39.25	11.33	16	24442	983	46660621
Eosinophilic granulomatosis with polyangiitis	38.65	11.33	19	24439	1817	46659787
Sinusitis	38.43	11.33	152	24306	129616	46531988
Nightmare	37.70	11.33	45	24413	16553	46645051
Sputum discoloured	34.70	11.33	38	24420	12740	46648864
Malaise	34.31	11.33	293	24165	330939	46330665
Productive cough	33.71	11.33	79	24379	50636	46610968
Paraesthesia oral	33.70	11.33	36	24422	11737	46649867
Obstructive airways disorder	33.19	11.33	38	24420	13374	46648230
Alkalosis hypochloraemic	33.12	11.33	9	24449	152	46661452
Throat tightness	32.90	11.33	47	24411	20592	46641012
Squamous cell carcinoma of the oral cavity	31.30	11.33	10	24448	302	46661302
Treatment failure	30.23	11.33	6	24452	93081	46568523
Off label use	29.02	11.33	102	24356	379739	46281865
Middle insomnia	28.84	11.33	30	24428	9485	46652119
Drug monitoring procedure not performed	28.84	11.33	10	24448	391	46661213
Miller Fisher syndrome	26.78	11.33	7	24451	101	46661503
Contraindicated product administered	26.28	11.33	5	24453	79942	46581662
Hyponatraemia	25.53	11.33	113	24345	101219	46560385
Bronchitis	25.07	11.33	116	24342	105863	46555741
Arterial spasm	24.13	11.33	6	24452	70	46661534
Differential white blood cell count abnormal	23.92	11.33	10	24448	655	46660949
Nasal discomfort	23.89	11.33	18	24440	3720	46657884
Transient ischaemic attack	23.88	11.33	55	24403	34848	46626756
Rash macular	23.84	11.33	39	24419	19221	46642383
Dysmetropsia	23.75	11.33	6	24452	75	46661529
Status asthmaticus	23.71	11.33	11	24447	925	46660679
Forced expiratory volume decreased	22.92	11.33	20	24438	5084	46656520
Urticaria	22.89	11.33	122	24336	117770	46543834
Limb injury	22.62	11.33	38	24420	19136	46642468
Synovitis	21.91	11.33	3	24455	61072	46600532
Idiopathic orbital inflammation	21.08	11.33	6	24452	121	46661483
Infective pulmonary exacerbation of cystic fibrosis	20.85	11.33	27	24431	10780	46650824
Eye movement disorder	19.97	11.33	18	24440	4775	46656829
Aspirin-exacerbated respiratory disease	19.60	11.33	9	24449	739	46660865
Systemic lupus erythematosus	19.56	11.33	5	24453	65175	46596429
Intentional overdose	19.45	11.33	5	24453	64939	46596665
Malignant neoplasm progression	19.44	11.33	5	24453	64921	46596683
Anxiety	19.33	11.33	162	24296	181795	46479809
Breast conserving surgery	19.12	11.33	9	24449	782	46660822
Gingival swelling	18.80	11.33	16	24442	3934	46657670
Pharyngeal swelling	18.74	11.33	15	24443	3388	46658216
Contusion	18.69	11.33	93	24365	87394	46574210
Skin fragility	18.35	11.33	8	24450	581	46661023
Pregnancy with implant contraceptive	18.24	11.33	12	24446	2000	46659604
Throat irritation	18.10	11.33	44	24414	28857	46632747
Infusion related reaction	17.88	11.33	16	24442	101192	46560412
Bronchial secretion retention	17.62	11.33	9	24449	934	46660670
Palpitations	17.42	11.33	97	24361	95162	46566442
Drug abuse	16.97	11.33	6	24452	63402	46598202
Dizziness	16.88	11.33	261	24197	340153	46321451
Nonspecific reaction	16.69	11.33	11	24447	1839	46659765
Retinopathy proliferative	16.56	11.33	4	24454	41	46661563
Bacterial disease carrier	16.52	11.33	8	24450	740	46660864
Tendonitis	16.45	11.33	28	24430	14249	46647355
Sleep disorder due to a general medical condition	16.30	11.33	14	24444	3485	46658119
Facial pain	16.22	11.33	20	24438	7605	46653999
Anaemia	16.13	11.33	74	24384	255705	46405899
Derealisation	15.98	11.33	8	24450	795	46660809
Rhinovirus infection	15.83	11.33	14	24444	3622	46657982
Aggression	15.73	11.33	36	24422	22708	46638896
Brain contusion	15.55	11.33	7	24451	549	46661055
Myalgia	15.49	11.33	114	24344	122974	46538630
Bladder irritation	15.29	11.33	5	24453	163	46661441
Nasal septum ulceration	15.27	11.33	3	24455	10	46661594
Gastric mucosa erythema	14.92	11.33	5	24453	176	46661428
Peripheral vascular disorder	14.90	11.33	17	24441	5960	46655644
Blood creatinine increased	14.84	11.33	11	24447	76392	46585212
Choking	14.73	11.33	20	24438	8356	46653248
Arthropathy	14.24	11.33	14	24444	84686	46576918
Cytomegalovirus enteritis	14.24	11.33	5	24453	203	46661401
Plasma cell myeloma	14.16	11.33	3	24455	44475	46617129
Platelet count decreased	14.15	11.33	19	24439	100005	46561599
Lip infection	14.04	11.33	4	24454	81	46661523
Oral mucosa erosion	13.69	11.33	8	24450	1082	46660522
Drug intolerance	13.68	11.33	36	24422	147013	46514591
Pruritus	13.64	11.33	190	24268	242162	46419442
Tongue pruritus	13.57	11.33	6	24452	451	46661153
Nasal septum perforation	13.48	11.33	7	24451	752	46660852
Febrile neutropenia	13.36	11.33	18	24440	94609	46566995
Antipsychotic drug level increased	13.32	11.33	12	24446	3180	46658424
Secretion discharge	13.25	11.33	20	24438	9199	46652405
Angioedema	13.21	11.33	48	24410	39294	46622310
Nasal congestion	13.14	11.33	55	24403	48058	46613546
Product administered to patient of inappropriate age	12.99	11.33	11	24447	2685	46658919
Gastroenteritis aeromonas	12.98	11.33	3	24455	25	46661579
Drug hypersensitivity	12.86	11.33	75	24383	243750	46417854
Necrosis ischaemic	12.77	11.33	7	24451	838	46660766
Mobility decreased	12.73	11.33	8	24450	60586	46601018
Nasal polyps	12.72	11.33	10	24448	2200	46659404
Enlarged uvula	12.68	11.33	4	24454	116	46661488
Rhinorrhoea	12.64	11.33	54	24404	47611	46613993
Dermatitis allergic	12.31	11.33	23	24435	12580	46649024
Dysphonia	12.17	11.33	46	24412	38368	46623236
Upper gastrointestinal haemorrhage	12.14	11.33	27	24431	16711	46644893
Sneezing	12.14	11.33	23	24435	12718	46648886
Headache	12.12	11.33	332	24126	478020	46183584
Subretinal haematoma	11.99	11.33	3	24455	36	46661568
Intraocular haematoma	11.99	11.33	3	24455	36	46661568
Migraine	11.94	11.33	70	24388	69956	46591648
Viral haemorrhagic cystitis	11.89	11.33	6	24452	607	46660997
Pericarditis constrictive	11.74	11.33	5	24453	343	46661261
Intentional product misuse	11.71	11.33	5	24453	47123	46614481
Post abortion haemorrhage	11.63	11.33	3	24455	41	46661563
Nasal discharge discolouration	11.61	11.33	8	24450	1440	46660164
Respiratory rate increased	11.34	11.33	21	24437	11412	46650192

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Asthma	336.41	12.37	217	15152	35957	29901152
Wheezing	134.92	12.37	118	15251	30820	29906289
Dyspnoea	86.30	12.37	368	15001	332927	29604182
Ballismus	57.78	12.37	12	15357	58	29937051
Anger	53.69	12.37	45	15324	11075	29926034
Lip swelling	52.29	12.37	47	15322	12697	29924412
Nightmare	50.47	12.37	45	15324	12031	29925078
Swollen tongue	48.97	12.37	46	15323	13146	29923963
Sleep terror	44.18	12.37	16	15353	727	29936382
Pharyngeal oedema	41.60	12.37	31	15338	6440	29930669
Blood immunoglobulin E increased	40.11	12.37	19	15350	1711	29935398
Lower respiratory tract infection	38	12.37	57	15312	26657	29910452
Anosmia	36.61	12.37	19	15350	2081	29935028
Cough	34.00	12.37	141	15228	125501	29811608
Nasal disorder	33.87	12.37	15	15354	1156	29935953
Nasal discomfort	33.39	12.37	15	15354	1196	29935913
Death	33.31	12.37	85	15284	357198	29579911
Attention-seeking behaviour	32.87	12.37	7	15362	39	29937070
Hyperkaliuria	32.71	12.37	9	15360	163	29936946
Infective pulmonary exacerbation of cystic fibrosis	32.02	12.37	30	15339	8542	29928567
Toxicity to various agents	31.27	12.37	27	15342	177156	29759953
Acquired macroglossia	31.15	12.37	6	15363	18	29937091
Malaise	31.03	12.37	168	15201	166794	29770315
Chronic obstructive pulmonary disease	28.56	12.37	69	15300	46057	29891052
Completed suicide	28.28	12.37	8	15361	99484	29837625
Dyspnoea at rest	27.57	12.37	17	15352	2589	29934520
Chorea	25.35	12.37	12	15357	1079	29936030
Crepitations	25.26	12.37	17	15352	3007	29934102
Chest discomfort	24.98	12.37	65	15304	45415	29891694
Drug abuse	24.46	12.37	6	15363	82066	29855043
Sputum discoloured	24.26	12.37	23	15346	6645	29930464
Daydreaming	23.82	12.37	9	15360	461	29936648
Neuropsychiatric symptoms	23.30	12.37	9	15360	490	29936619
Neonatal hyponatraemia	22.93	12.37	6	15363	89	29937020
Central obesity	22.32	12.37	9	15360	549	29936560
Productive cough	22.07	12.37	48	15321	29905	29907204
Crying	21.66	12.37	20	15349	5589	29931520
Gastric ulcer perforation	21.37	12.37	10	15359	876	29936233
Gastrointestinal tract irritation	21.32	12.37	7	15362	236	29936873
Abnormal behaviour	21.13	12.37	43	15326	25580	29911529
Inflammatory myofibroblastic tumour	20.54	12.37	6	15363	136	29936973
Palpitations	20.54	12.37	50	15319	33523	29903586
Suicidal ideation	20.22	12.37	52	15317	36062	29901047
Malignant neoplasm progression	20.19	12.37	6	15363	72281	29864828
Cervicogenic headache	20.08	12.37	4	15365	15	29937094
Obstructive airways disorder	20.06	12.37	24	15345	9035	29928074
Micturition urgency	19.56	12.37	17	15352	4390	29932719
Urticaria	19.48	12.37	67	15302	54539	29882570
Angioedema	18.73	12.37	49	15320	34335	29902774
Spleen congestion	18.33	12.37	7	15362	369	29936740
Paraesthesia oral	18.05	12.37	15	15354	3646	29933463
Renal failure	17.89	12.37	24	15345	128942	29808167
Dizziness	17.76	12.37	165	15204	194744	29742365
Platelet count decreased	17.71	12.37	17	15352	106112	29830997
Product monitoring error	17.51	12.37	11	15358	1730	29935379
Neuropsychiatric syndrome	17.48	12.37	5	15364	105	29937004
Hypoproteinaemia	17.09	12.37	11	15358	1805	29935304
Ageusia	17.06	12.37	22	15347	8931	29928178
Eye swelling	17.04	12.37	22	15347	8942	29928167
Nasal septum perforation	16.89	12.37	5	15364	119	29936990
Locked-in syndrome	16.79	12.37	6	15363	262	29936847
Mesothelioma	16.79	12.37	7	15362	465	29936644
Neutropenia	16.76	12.37	25	15344	128515	29808594
Blood count abnormal	16.76	12.37	25	15344	11627	29925482
Neonatal seizure	16.68	12.37	7	15362	473	29936636
Ejaculation failure	16.19	12.37	8	15361	790	29936319
Convulsive threshold lowered	16.02	12.37	7	15362	522	29936587
Multifocal motor neuropathy	15.85	12.37	4	15365	51	29937058
Self-injurious ideation	15.77	12.37	10	15359	1599	29935510
Depressed mood	15.76	12.37	30	15339	16999	29920110
Thrombocytopenia	15.69	12.37	29	15340	137015	29800094
Eosinophilic pneumonia chronic	15.37	12.37	4	15365	58	29937051
Anaphylactic reaction	15.36	12.37	40	15329	27942	29909167
Rhinitis	15.22	12.37	15	15354	4544	29932565
Ocular discomfort	14.87	12.37	9	15360	1326	29935783
Lower respiratory tract congestion	14.39	12.37	8	15361	1005	29936104
Renal aplasia	14.36	12.37	7	15362	671	29936438
Disease progression	14.27	12.37	12	15357	79862	29857247
Aortic dissection	14.15	12.37	11	15358	2431	29934678
Graft versus host disease in gastrointestinal tract	13.95	12.37	12	15357	3057	29934052
Plasma cell myeloma	13.94	12.37	5	15364	53457	29883652
Tryptase increased	13.94	12.37	5	15364	221	29936888
Product administered to patient of inappropriate age	13.76	12.37	11	15358	2532	29934577
Nasal inflammation	13.66	12.37	5	15364	234	29936875
Leukopenia	13.42	12.37	6	15363	56153	29880956
Mood swings	13.39	12.37	18	15351	7608	29929501
Weaning failure	13.22	12.37	5	15364	257	29936852
Bronchospasm	13.21	12.37	21	15348	10317	29926792
Rash papular	13.08	12.37	19	15350	8626	29928483
Cryptorchism	12.99	12.37	9	15360	1668	29935441
Sinusitis	12.85	12.37	42	15327	33303	29903806
Nasal congestion	12.82	12.37	29	15340	18537	29918572
Apnoeic attack	12.74	12.37	5	15364	284	29936825
Febrile neutropenia	12.72	12.37	22	15347	106671	29830438
Violence-related symptom	12.66	12.37	6	15363	541	29936568
Tendonitis	12.66	12.37	18	15351	8018	29929091
Cystic fibrosis	12.65	12.37	10	15359	2264	29934845
Pain	12.50	12.37	46	15323	172595	29764514
Eosinophilia	12.50	12.37	32	15337	22128	29914981

Pharmacologic Action:

Source	Code	Description
ATC	A07EA07	ALIMENTARY TRACT AND METABOLISM ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS INTESTINAL ANTIINFLAMMATORY AGENTS Corticosteroids acting locally
ATC	D07AC15	DERMATOLOGICALS CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS CORTICOSTEROIDS, PLAIN Corticosteroids, potent (group III)
ATC	D07CC04	DERMATOLOGICALS CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS Corticosteroids, potent, combinations with antibiotics
ATC	R01AD01	RESPIRATORY SYSTEM NASAL PREPARATIONS DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE Corticosteroids
ATC	R03AK08	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
ATC	R03AK13	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
ATC	R03AL09	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
ATC	R03BA01	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS Glucocorticoids
CHEBI has role	CHEBI:35472	anti-inflammatory drugs
CHEBI has role	CHEBI:49167	anti-asthmatic agents
CHEBI has role	CHEBI:38070	antiarrhythmic agent
CHEBI has role	CHEBI:50266	prodrugs
MeSH PA	D018927	Anti-Asthmatic Agents
MeSH PA	D000893	Anti-Inflammatory Agents
MeSH PA	D005938	Glucocorticoids
MeSH PA	D006728	Hormones
MeSH PA	D019141	Respiratory System Agents
MeSH PA	D001993	Bronchodilator Agents
MeSH PA	D018373	Peripheral Nervous System Agents
FDA EPC	N0000175576	Corticosteroid
FDA MoA	N0000175450	Corticosteroid Hormone Receptor Agonists

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Vasomotor rhinitis	indication	8229003	DOID:4730
Nasal polyp	indication	52756005
Allergic rhinitis	indication	61582004
Rhinitis	indication	70076002	DOID:4483
Asthma	indication	195967001	DOID:2841
Asthma management	indication	406162001
Severe chronic obstructive pulmonary disease	off-label use	313299006
Mycosis	contraindication	3218000	DOID:1564
Ocular hypertension	contraindication	4210003	DOID:9282
Inactive tuberculosis	contraindication	11999007
Epistaxis	contraindication	12441001
Measles	contraindication	14189004	DOID:8622
Disease caused by parasite	contraindication	17322007
Glaucoma	contraindication	23986001	DOID:1686
Acute tuberculosis	contraindication	25629007
Perforation of nasal septum	contraindication	80142000
Bacterial infectious disease	contraindication	87628006
Mycobacteriosis	contraindication	88415009
Operation on nose	contraindication	88733004
Bilateral cataracts	contraindication	95722004
Ophthalmic herpes simplex	contraindication	186542001
Disease of liver	contraindication	235856003	DOID:409
Varicella-zoster virus infection	contraindication	309465005
Adrenal cortical hypofunction	contraindication	386584007	DOID:10493
Exposure to varicella	contraindication	444453009
Nasal Trauma	contraindication
Nasal Candidiasis	contraindication
Nasal Septal Ulcers	contraindication
Uncontrolled Bacterial Infections	contraindication
Untreated Fungal Infection	contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	12.01	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Glucocorticoid receptor	Nuclear hormone receptor	P04150	GCR_HUMAN	AGONIST	Ki	8.43	DRUG MATRIX	CHEMBL
Matrix metalloproteinase-9	Enzyme	P14780	MMP9_HUMAN		IC50	5.70	CHEMBL
Interleukin-5	Cytokine	P05113	IL5_HUMAN		IC50	4.57	CHEMBL
Glucocorticoid receptor	Transcription factor		GCR_RAT		IC50	8.54	CHEMBL
Interleukin-5	Unclassified		IL5_MOUSE		IC50	4.58	CHEMBL
Progesterone receptor	Transcription factor		Q690N0_BOVIN		Ki	7.57	CHEMBL
Androgen receptor	Transcription factor		ANDR_RAT		Ki	5.96	CHEMBL

External reference:

ID	Source
5B307S63B2	UNII
D00689	KEGG_DRUG
77011-63-3	SECONDARY_CAS_RN
4419-39-0	SECONDARY_CAS_RN
4018793	VANDF
4019625	VANDF
C0004906	UMLSCUI
C0004905	UMLSCUI
CHEBI:3002	CHEBI
CHEBI:3001	CHEBI
CHEMBL1200500	ChEMBL_ID
DB00394	DRUGBANK_ID
CHEMBL1370	ChEMBL_ID
CHEMBL1586	ChEMBL_ID
D001507	MESH_DESCRIPTOR_UI
D019819	MESH_DESCRIPTOR_UI
21700	PUBCHEM_CID
5894	IUPHAR_LIGAND_ID
2307	INN_ID
KGZ1SLC28Z	UNII
20469	PUBCHEM_CID
7059	IUPHAR_LIGAND_ID
1347	RXNORM
1167	MMSL
4249	MMSL
71834	MMSL
8263	MMSL
d00760	MMSL
002179	NDDF
004947	NDDF
116574000	SNOMEDCT_US
116575004	SNOMEDCT_US
1389007	SNOMEDCT_US
426017007	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
BECONULLSEAQ	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0388	SPRAY, SUSPENSION	42 ug	NULLSAL	NDA	20 sections
BECONULLSE AQ	HUMAN PRESCRIPTION DRUG LABEL	1	16590-030	SPRAY, SUSPENSION	42 ug	NULLSAL	NDA	13 sections
QVAR	HUMAN PRESCRIPTION DRUG LABEL	1	16590-860	AEROSOL, METERED	40 ug	RESPIRATORY (INHALATION)	NDA	26 sections
QVAR	HUMAN PRESCRIPTION DRUG LABEL	1	50090-1342	AEROSOL, METERED	80 ug	RESPIRATORY (INHALATION)	NDA	28 sections
QVAR	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3033	AEROSOL, METERED	40 ug	RESPIRATORY (INHALATION)	NDA	28 sections
QVAR REDIHALER	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3459	AEROSOL, METERED	80 ug	RESPIRATORY (INHALATION)	NDA	16 sections
QVAR REDIHALER	HUMAN PRESCRIPTION DRUG LABEL	1	50090-5031	AEROSOL, METERED	40 ug	RESPIRATORY (INHALATION)	NDA	17 sections
QVAR REDIHALER	HUMAN PRESCRIPTION DRUG LABEL	1	50090-5032	AEROSOL, METERED	80 ug	RESPIRATORY (INHALATION)	NDA	17 sections
QVAR REDIHALER	HUMAN PRESCRIPTION DRUG LABEL	1	53002-2436	AEROSOL, METERED	40 ug	RESPIRATORY (INHALATION)	NDA	16 sections
QVAR REDIHALER	HUMAN PRESCRIPTION DRUG LABEL	1	53002-3477	AEROSOL, METERED	80 ug	RESPIRATORY (INHALATION)	NDA	16 sections
QVAR	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5857	AEROSOL, METERED	40 ug	RESPIRATORY (INHALATION)	NDA	14 sections
QVAR	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5858	AEROSOL, METERED	80 ug	RESPIRATORY (INHALATION)	NDA	14 sections
QVAR REDIHALER	HUMAN PRESCRIPTION DRUG LABEL	1	59310-302	AEROSOL, METERED	40 ug	RESPIRATORY (INHALATION)	NDA	17 sections
QVAR REDIHALER	HUMAN PRESCRIPTION DRUG LABEL	1	59310-304	AEROSOL, METERED	80 ug	RESPIRATORY (INHALATION)	NDA	17 sections
QNULLSL	HUMAN PRESCRIPTION DRUG LABEL	1	59310-406	AEROSOL, METERED	40 ug	NULLSAL	NDA	27 sections
QNULLSL	HUMAN PRESCRIPTION DRUG LABEL	1	59310-410	AEROSOL, METERED	80 ug	NULLSAL	NDA	27 sections